로그인시 본인확인과정이 필요할 수 있습니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기
| 국가/구분 | United States(US) Patent 등록 |
|---|---|
| 국제특허분류(IPC7판) |
|
| 출원번호 | US-0503625 (2010-10-29) |
| 등록번호 | US-9855212 (2018-01-02) |
| 국제출원번호 | PCT/US2010/054871 (2010-10-29) |
| §371/§102 date | 20120423 (20120423) |
| 국제공개번호 | WO2011/053875 (2011-05-05) |
| 발명자 / 주소 |
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 | 피인용 횟수 : 0 인용 특허 : 335 |
Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are ef
Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.
1. A method for treating drug-resistant tuberculosis in a human subject in need thereof, comprising: pretreating the subject with intravenous administration of a pretreatment composition comprising about 50 mg to about 60 mg dimethylsulfoxide DMSO; andadministering to the pretreated subject a formul
1. A method for treating drug-resistant tuberculosis in a human subject in need thereof, comprising: pretreating the subject with intravenous administration of a pretreatment composition comprising about 50 mg to about 60 mg dimethylsulfoxide DMSO; andadministering to the pretreated subject a formulation comprising therapeutic agents dissolved in DMSO, via an inhalant device selected from the group consisting of: an inhaler, a nebulizer and a ventilator,wherein the therapeutic agents comprise three or more compounds selected from the group consisting of: streptomycin, isoniazid, rifampicin, pyrazinamide, and ethambutol. 2. The method of claim 1, wherein the total formulation volume is about 3 ml. 3. The method of claim 1, wherein the formulation is administered to the subject at least three times daily. 4. The method of claim 1, wherein the formulation comprises a daily dose of: rifampicin in an amount ranging from about 500 mg to about 700 mg,isoniazid in an amount ranging from about 200 mg to about 400 mg,pyrazinamide in an amount ranging from about 2.0 g to about 3.0 g, andethambutol in an amount ranging from about 1.0 g to about 2.0 g. 5. The method of claim 4, wherein the formulation comprises a daily dose of about 600 mg rifampicin, 300 mg isoniazid, 2.4 g pyrazinamide, and 1.2 g ethambutol. 6. The method of claim 1, wherein the inhalant device is configured to generate particles of the formulation that range in size from about 0.5 um to about 5 um. 7. The method of claim 1, wherein the formulation further comprises an odor reducing compound selected from the group consisting of urea and a sulfur binding compound. 8. The method of claim 7, wherein the odor reducing compound reduces the odor associated with DMSO. 9. The method of claim 1, wherein the formulation comprises a daily dose of streptomycin in an amount ranging from about 10 mg to about 200 g. 10. The method of claim 1, wherein the DMSO sensitizes the drug-resistant tuberculosis bacteria by increasing the permeability of the bacteria to the therapeutic agents. 11. A method for treating drug-resistant tuberculosis, comprising: intravenously administering a pretreatment composition comprising about 50 mg to about 60 mg dimethylsulfoxide (DMSO) to a subject having drug-resistant tuberculosis, and thenadministering a formulation comprising DMSO and therapeutic agents to the subject via an inhalant device,wherein the inhalant device is configured to deliver the formulation to directly contact drug-resistant tuberculosis bacteria in the subject's lung tissue, wherein the inhalant device is an inhaler, a nebulizer, or a ventilator;wherein the therapeutic agents comprise a daily dose of: rifampicin in an amount ranging from about 500 mg to about 700 mg,isoniazid in an amount ranging from about 200 mg to about 400 mg,pyrazinamide in an amount ranging from about 2.0 g to about 3.0 g, andstreptomycin in an amount ranging from about 10 mg to about 200 g per kg of body weight,wherein the DMSO in the formulation sensitizes the drug-resistant tuberculosis bacteria to at least one of the isoniazid, rifampicin, pyrazinamide, and streptomycin, thereby generating sensitized tuberculosis bacteria, andwherein at least one of isoniazid, rifampicin, pyrazinamide, and streptomycin lethally inhibits the sensitized tuberculosis bacteria, thereby treating the drug-resistant tuberculosis. 12. The method of claim 11, wherein the therapeutic agents further comprise ethambutol in an amount ranging from about 1.0 g to about 2.0 g.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.